An Open-label, Randomized, Single-dose, Oral Administration, 2-sequence, 2- Period, Crossover Study to Evaluate Bioequivalence Between YHP2305 and YHR2404 in Healthy Subjects
Latest Information Update: 11 Nov 2024
Price :
$35 *
At a glance
- Drugs YHP 2305 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Yuhan
- 07 Nov 2024 Status changed from recruiting to completed.
- 04 Oct 2024 New trial record